Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
NMTC Stock Chart & Stats
$0.67
-$0.09(-8.05%)
At close: 4:00 PM EST
$0.67
-$0.09(-8.05%)
Day’s Range― - ―
52-Week Range$0.40 - $1.16
Previous CloseN/A
Volume212.44K
Average Volume (3M)532.45K
Market Cap
$33.70M
Enterprise Value$32.36M
Total Cash (Recent Filing)$3.56M
Total Debt (Recent Filing)$110.37K
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 07, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding50,525,993
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.71
Enterprise Value/Gross Profit6.77
Enterprise Value/Ebitda-4.74
Forecast
1Y Price Target
$2.25Price Target Upside235.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$11.37M
Bulls Say, Bears Say
Bulls Say
Distribution PartnershipSupport from a major distribution partner has expanded the trained sales footprint and driven meaningful product revenue growth, improving market access and commercialization prospects.
Pipeline Expansion And New IndicationsDevelopment of a percutaneous spinal cord paddle lead and an sEEG-based drug delivery system creates pathways for strategic partnerships and diversification into larger chronic pain and drug delivery markets.
Product DifferentiationOneRF Ablation System combines high-definition diagnostic monitoring with ablation capability in a single device, allowing clinicians to diagnose and treat in one procedure and supporting faster clinical adoption.
Bears Say
Profitability RiskThe company’s continued net losses represent a financial risk that could weigh on the stock if revenue growth does not keep pace with expenses.
Revenue VolatilityRevenue patterns can be uneven because sales depend on the timing of partner stocking orders, increasing quarter-to-quarter volatility and complicating forecasting.
Rising Operating Expenses And Dilution RiskHigher expected operating expenses are projected to widen GAAP losses per share, which may increase the need for additional financing and potential shareholder dilution.
NeuroOne Medical Technologies News
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
NeuroOne Medical Technologies lowest stock price was $0.40 and its highest was $1.16 in the past 12 months.
What is NeuroOne Medical Technologies’s market cap?
NeuroOne Medical Technologies’s market cap is $33.70M.
When is NeuroOne Medical Technologies’s upcoming earnings report date?
NeuroOne Medical Technologies’s upcoming earnings report date is May 07, 2026 which is in 65 days.
How were NeuroOne Medical Technologies’s earnings last quarter?
NeuroOne Medical Technologies released its earnings results on Feb 17, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.01.
Is NeuroOne Medical Technologies overvalued?
According to Wall Street analysts NeuroOne Medical Technologies’s price is currently Undervalued.
Does NeuroOne Medical Technologies pay dividends?
NeuroOne Medical Technologies does not currently pay dividends.
What is NeuroOne Medical Technologies’s EPS estimate?
NeuroOne Medical Technologies’s EPS estimate is -0.04.
How many shares outstanding does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies has 50,525,993 shares outstanding.
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
NeuroOne Medical Technologies reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -16.482%.
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
Currently, no hedge funds are holding shares in NMTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroOne Medical Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.25 (235.82% Upside)
$2.25 (235.82% Upside)
Insider Transactions
Bought Shares
Worth $670.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.9%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
-91.34%
Trailing 12-Months
Asset Growth
120.24%
Trailing 12-Months
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
NMTC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral — The call highlighted multiple operational and clinical achievements (accelerated programs, regulatory clearance, strong early clinical outcomes, product adoption, and meaningful fiscal 2026 revenue guidance of at least $10.5M). However, these positives are offset by near-term financial headwinds including a year-over-year revenue decline driven by the absence of prior license revenue, a drop in gross margin, a swing to a net loss, and a substantial reduction in cash on hand with funding only assured through fiscal 2026 unless milestones are met. The company shows promising commercial and development momentum but faces tangible liquidity and margin pressures that moderate the overall outlook.View all NMTC earnings summariesNMTC Stock 12 Month Forecast
Average Price Target
$2.25
▲(235.82% Upside)
Technical Analysis
Sensus Healthcare
―
Electrocore
―
Modular Medical
―
Vicarious Surgical
―
Inspira Technologies Oxy BHN
―
Ownership Overview
11.39% Insiders
3.40% Mutual Funds
15.20% Other Institutional Investors
67.47% Public Companies and
Individual Investors